Summary
This study compared the efficacy and safety of 5-fluorouracil (5-FU) monotherapy to that of 5-FU combined with natural human interferon-β (IFN-β) in patients with unresectable, advanced colorectal carcinoma. Forty-nine chemotherapy-naive patients were randomized to 5-FU alone or to the combination. All patients received 750 mg m–2 day–1 5-FU for 5 days by continuous intravenous (i.v.) infusion, followed after day 15 by a weekly i.v. bolus of 750 mg m–2. IFN-β was injected intramuscularly three times weekly at 9 M IU. Treatment continued for 52 weeks, or until disease progression or intolerable toxicity. Clinical endpoints were tumor response, time to progression, survival and toxicity. The addition of IFN-β to 5-FU significantly improved response rate (33.3% vs 4.5% for evaluable patients; P = 0.021), time to progression (median 7.2 vs 4.2 months; P = 0.0435), and survival time (median 15.9 vs 7.2 months; P = 0.038) without significantly increasing toxicity compared to 5-FU alone. Cumulative 5-FU dose was higher with combined therapy (P < 0.001): more patients receiving monotherapy discontinued treatment because of disease progression. Fever was more frequent with combined therapy (P = 0.008); there were no other differences in toxicity. The only grade IV toxicity observed was neutropenia (two patients per group). A randomized phase III trial has been initiated to confirm the synergy between 5-FU and IFN-β.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Beard, C. M., Spencer, C. J., Weiland, L. H., O’Fallon, W. M. & Melton, L. J. 3rd (1995). Trends in colorectal cancer over half a century in Rochester, Minnesota, 1940–1989. Ann Epidemiol 5: 210–214.
Borden, E. C., Hogan, T. F. & Voelkel, J. G. (1982). Comparative antiproliferative activity in vitro of natural interferons alpha or beta for diploid and transformed human cells. Cancer Res 42: 4989–4953.
Carter, S. K. (1976). Large bowel cancer: The current status of treatment. J Natl Cancer Inst 56: 3–10.
Corfu-A Study, Group (1995). A phase III randomised study of two fluorouracil combinations of either interferon α 2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13: 921–928.
Dufour, P., Husseini, F., Dreyfus, B., Cure, H., Martin, C., Prevost, G., Olivier, J. P., Dumas, F., Duclos, B., Olivares, R., Leszler, A., Bergerat, J. P., Audhuy, B., Thill, L. & Oberling, F. (1996). 5-Fluorouracil versus 5-fluorouracil plus α-interferon as treatment of metastatic colorectal carcinoma. A randomized study. Ann Oncol 7: 575–579.
Ehrlichman, C., Fine, S., Wong, A. & Elhakim, T. (1988). A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469–475.
Greco, J., Figlin, R., York, M., Einhorn, L., Schilsky, R., Marshall, E. M., Buys, S. S., Froimtchuk, M. J., Schuller, J., Schuchter, L., Buyse, M., Ritter, L., Man, A. & Yap, A. K. (1996). Phase III randomized study to compare interferon α-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14: 2674–2681.
Gugliemi, A., Mori, A., Aschele, C., Rosso, R. & Sobrero, A. (1984). 5-Fluorouracil plus beta interferon against human colon carcinoma cells in vitro. J Interferon Res 12: S168
Heidelberger, C., Chaudhari, N. K. & Danneberg, P. et al (1957). Fluorinated pyrimidines. A new class of tumour-inhibitory compounds. Nature 179: 663–666.
Hill, M., Norman, A., Cunningham, D., Findlay, M., Nicholson, V., Hill, A., Iveson, A., Evans, C., Joffe, J. & Nicholson, M. et al (1995). Royal Marsden phase III trial of 5-fluorouracil with or without interferon alfa 2b in advanced colorectal cancer. J Clin Oncol 13: 1297–1302.
Jäger, E., Heike, M., Bernard, H., Klein, O., Bernhard, G., Lautz, D., Michaelis, J., Meyer zum Bushenfelde, K. H. & Knuth, A. (1996). Weekly combined high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. J Clin Oncol 14: 2274–2279.
Kase, S., Kubota, T., Watanabe, M., Furukawa, T., Tanino, H., Ishibiki, K., Teramoto, T. & Kitajima, M. (1993). Interferon beta increases antitumour activity of 5-fluorouracil against human colon carcinoma cell lines in vitro and in vivo. Anticancer Res 13: 69–74.
Kemeny, N., Younes, A., Seiter, K., Kelsen, D., Sammarco, P., Adams, L., Derby, S., Murray, P. & Houston, C. (1990). Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 66: 2470–2475.
Köhne, C. H., Wilke, H., Hecker, H., Schoffski, P., Kaufer, C., Rauschecker, H., Andreesen, R., Ohl, U., Lange, H. J. & Klaassen, U. et al (1995). Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. Ann Oncol 6: 461–466.
Leichman, C. G., Fleming, T. R., Muggia, F. M., Tangen, C. M., Ardalan, B., Doroshow, J. H., Meyers, F. J., Holcombe, R. F., Weiss, G. R., Mangalik, A. & Macdonald, J. S. (1995). Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13: 1303–1311.
Moertel, C. G. (1975). Clinical management of advanced gastrointestinal cancer. Cancer 36: 675–682.
Moertel, C. G. (1982). Large bowel. In Cancer Medicine 2nd edn, Holland JF, Frei E (eds), pp. 830–1859. Lea & Febiger: Philadelphia, PA
Netherlands Cancer, Registry (1989). Incidence of Cancer in the Netherlands. First Report of the Netherlands Cancer Registry, pp. 36–42
O’Dwyer, P. J., Ryan, L. M., Valone, F. H., Hines, J. D., Arbuck, S. G., Wadler, S., Haller, D. G., Mayer, R. J. & Benson, A. B. (1996). Phase III trial of biochemical modulation of 5-fluoruracil by iv or oral leucovorin or by interferon in advanced colorectal cancer: an ECOG/CALBG phase III trial. Proc ASCO 15: 207 (abstract 469)
Pazdur, R., Ajani, J. A., Patt, Y. Z., Winn, R., Jackson, D., Shepard, B., DuBrow, R., Campos, L., Quaraishi, M. & Faintuch, J. et al (1990). Phase III study of fluorouracil and recombinant interferon α-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8: 2027–2031.
Piedbois, P., Buyse, M., Rustum, Y., Machover, D., Erlichman, C., Carlson, R. W., Valone, F., Labianca, R., Doroshow, J. H. & Petrelli (1992). Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896–903.
Platanias, L. C., Uddin, S. & Colamonici, O. R. (1994). Tyrosine phosphorylation of A and B subunits of type I interferon receptor. J Biol Chem 269: 17761–17764.
Poon, M. A., O’Connell, M. J., Moertel, C. G., Wieand, H. S., Cullinan, S. A., Everson, L. K., Krrok, J. E., Maillard, J. A., Laurie, J. A. & Tschetter, L. K. et al (1989). Biochemical modulation of fluorouracil: evidence of significant improvement of survival time and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407–1418.
Ruzicka, F. J., Jach, M. E. & Borden, E. C. (1987). Binding of recombinant-produced interferon-beta-ser to human lymphoblastoid cells. J Biol Chem 269: 17761–17764.
Schwartz, E. L., Baptiste, N., Wadler, S. & Makower, D. (1995). Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 270: 19073–19077.
Taniguchi, T., Manei, N., Schwarzstein, M., Nagata, S., Muramatsu, M. & Weissman, C. (1980). Human leukocyte and fibroblast interferons are structurally related. Nature 285: 547–549.
Wadler, S., Schwartz, E. L., Goldman, M., Lyver, A., Rader, M., Zimmerman, M., Itri, L., Weinberg, V. & Wiernick, P. H. (1989). Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769–1775.
Wadler, S., Haynes, H., Tenteromano, L., Kaleya, R. & Rozenblit, P. H. (1995). Results of sequential phase II clinical trials of 5-fluorouracil (5FU) + interferon-beta (IFNβ) in patients with advanced colorectal cancer. Proc ASCO 14: 205 (abstract 499)
Wong, V. Y. L., Rieman, D. J., Aronson, L., Dalton, B. J., Greig, R. & Anzano, M. A. (1989). Growth inhibitory activity of interferon-beta against human colorectal carcinoma cell lines. Int J Cancer 43: 526–530.
World Health Organization (1979). Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48, World Health Organization: Geneva, Switzerland
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Villar-Grimalt, A., Candel, M., Massuti, B. et al. A randomized phase II trial of 5-fluorouracil, with or without human interferon-β, for advanced colorectal cancer. Br J Cancer 80, 786–791 (1999). https://doi.org/10.1038/sj.bjc.6690422
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690422